These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 8646356)

  • 1. Effective therapy: repeat limb perfusion for recurrent melanoma.
    Krementz ET
    J Am Coll Surg; 1996 Jun; 182(6):547-8. PubMed ID: 8646356
    [No Abstract]   [Full Text] [Related]  

  • 2. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical results of extremity perfusion in malignant melanoma].
    Huber R; Stützer H; Krüger I
    Zentralbl Chir; 1996; 121(3):234-42. PubMed ID: 8867351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion for melanoma.
    Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
    J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
    Pace M; Gattai R; Mascitelli EM; Millanta L
    J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma--therapeutic applications and results].
    Eichfeld U; Gläser A; Schneider G; Kraus J; Pauer HJ; Schwarz I
    Zentralbl Chir; 1993; 118(2):63-8. PubMed ID: 7682024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

  • 9. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of regional lymph node excision for prognosis of advanced malignant melanoma treated by perfusion of the extremity].
    Huber R; Krüger I; Stützer H
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():118-21. PubMed ID: 9101808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preventive lymph node excision in the treatment concept of melanoma of the extremities].
    Binder J; Henneking K
    Zentralbl Chir; 1996; 121(6):474-7. PubMed ID: 8767334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
    Santillan AA; Zager JS
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma.
    Lindnér P; Doubrovsky A; Kam PC; Thompson JF
    Ann Surg Oncol; 2002 Mar; 9(2):127-36. PubMed ID: 11888868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic hyperthermic limb perfusion in stage I melanoma.
    Krige JE; King HS; Strover RM
    Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
    Olofsson Bagge R; Mattsson J; Hafström L
    Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of isolated limb perfusion to manage recurrent malignant melanoma.
    Ma D; Ariyan S
    Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Regional isolated perfusion: also applicable in elderly patients].
    Noorda EM; Vrouenraets BC; Nieweg OE; Kroon BB
    Ned Tijdschr Geneeskd; 2003 Mar; 147(12):529-33. PubMed ID: 12693077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.